Zaman Khalequz, Carraro Silvia, Doherty Joseph, Henderson Edward M, Lendermon Elizabeth, Liu Lei, Verghese George, Zigler Molly, Ross Mark, Park Edward, Palmer Lisa A, Doctor Allan, Stamler Jonathan S, Gaston Benjamin
Department of Pediatrics, University of Virginia Health System, Pediatric Respiratory Medicine, Box 800386, Charlottesville, VA 22908, USA.
Mol Pharmacol. 2006 Oct;70(4):1435-42. doi: 10.1124/mol.106.023242. Epub 2006 Jul 20.
The endogenous bronchodilator, S-nitrosoglutathione (GSNO), increases expression, maturation, and function of both the wild-type and the DeltaF508 mutant of the cystic fibrosis transmembrane conductance regulatory protein (CFTR). Though transcriptional mechanisms of action have been identified, GSNO seems also to have post-transcriptional effects on CFTR maturation. Here, we report that 1) GSNO is only one of a class of S-nitrosylating agents that, at low micromolar concentrations, increase DeltaF508 and wild-type CFTR expression and maturation; 2) NO itself (at these concentrations) and 8-bromocyclic GMP are minimally active on CFTR; 3) a novel agent, S-nitrosoglutathione diethyl ester, bypasses the need for GSNO bioactivation by gamma-glutamyl transpeptidase to increase CFTR maturation; 4) surprisingly, expression-but not S-nitrosylation-of cysteine string proteins (Csp) 1 and 2 is increased by GSNO; 5) the effect of GSNO to increase full maturation of wild-type CFTR is inhibited by Csp silencing (si)RNA; 6) proteins relevant to CFTR trafficking are SNO-modified, and SNO proteins traffic through the endoplasmic reticulum (ER) and Golgi after GSNO exposure; and 7) GSNO alters the interactions of DeltaF508 CFTR with Csp and Hsc70 in the ER and Golgi. These data suggest that GSNO is one of a class of S-nitrosylating agents that act independently of the classic NO radical/cyclic GMP pathway to increase CFTR expression and maturation. They also suggest that the effect of GSNO is dependent on Csp and on intracellular SNO trafficking. We speculate that these data will be of relevance to the development of NO donor-based therapies for CF.
内源性支气管扩张剂S-亚硝基谷胱甘肽(GSNO)可增加囊性纤维化跨膜传导调节蛋白(CFTR)野生型和DeltaF508突变体的表达、成熟及功能。尽管已经确定了其转录作用机制,但GSNO似乎对CFTR成熟也有转录后效应。在此,我们报告:1)GSNO只是一类亚硝基化剂中的一种,在低微摩尔浓度下,它可增加DeltaF508和野生型CFTR的表达及成熟;2)一氧化氮本身(在这些浓度下)和8-溴环鸟苷酸对CFTR的活性极小;3)一种新型试剂S-亚硝基谷胱甘肽二乙酯无需γ-谷氨酰转肽酶对GSNO进行生物活化就能增加CFTR成熟;4)令人惊讶的是,GSNO可增加半胱氨酸串珠蛋白(Csp)1和2的表达而非亚硝基化;5)Csp沉默(si)RNA可抑制GSNO增加野生型CFTR完全成熟的作用;6)与CFTR转运相关的蛋白质被亚硝基化修饰,且在GSNO作用后,亚硝基化蛋白质通过内质网(ER)和高尔基体进行转运;7)GSNO改变了DeltaF508 CFTR与ER和高尔基体中Csp及热休克同源蛋白70(Hsc70)的相互作用。这些数据表明,GSNO是一类亚硝基化剂中的一种,其作用独立于经典的一氧化氮自由基/环鸟苷酸途径,可增加CFTR的表达及成熟。它们还表明,GSNO的作用依赖于Csp和细胞内亚硝基化转运。我们推测这些数据将与基于一氧化氮供体的囊性纤维化治疗方法的开发相关。